Biopharma Leads Networking Pharma 
pharmaphorum
DECEMBER 4, 2022
The biopharma industry is worse, with women only accounting for 8% of CEO roles. According to the Women in Tech Network , due to lack of role models and significant personal sacrifices they’ve had to make, women leave the tech industry at a 45% higher rate than men. to take charge of their own career goals and aspirations.
Pharma Marketing Network
MARCH 30, 2023
Mary brings to the HBA 30 years of experience leading the strategic integration of corporate branding, marketing, health equity, inclusion, and digital innovation for biopharma, healthcare, and media companies. In 2022, she co-created Real Chemistry’s first Real Health Equity Summit “Changing Out Loud” during the J.P.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JUNE 29, 2022
Meanwhile, the pharma industry is undergoing somewhat of a transformation itself. In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. The impact could be huge for the biopharma industry. Developing best-in-class speciality enzymes.
PM360
OCTOBER 3, 2023
PRODUCT LAUNCH OF THE YEAR NEXTSTELLIS (Mayne Pharma and EVERSANA INTOUCH) RELAUNCH/REVITALIZATION OF THE YEAR VRAYLAR (AbbVie Inc. Diversity/Multicultural: Anna Czene, Vice President, Corporate Communications & DEI Lead, CareDx, Inc. and Publicis NY) BRAND CHAMPION AWARD WINNERS Autoimmune/Rheumatology: Katrina Sergeev Gary, Sr.
Clarivate
MAY 14, 2024
While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7
pharmaphorum
SEPTEMBER 28, 2022
In recent years, the biopharma market has become progressively complex. HTA agencies can assist biopharma companies at the early stages of development to ensure they are meeting the expectations of payers. The implementation of the resulting recommendations can reduce payer uncertainty and lead to optimized HTA submissions.
Clarivate
MAY 8, 2023
That was the overarching sentiment from the experienced group of biopharma leaders that formed the panel discussion chaired by Mike Ward, Clarivate Global Head of Life Sciences and Healthcare Thought Leadership, at this year’s AngloNordic Life Science conference. Timing is everything. It’s a lesson in doing things too early,” said Martin.
Expert insights. Personalized for you.
97 
Let's personalize your content